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Abstract
Objective: The oxidant/antioxidant state in septic patients has only been studied in small series. We wished to determine
whether malondialdehyde (MDA) serum levels were associated with severity and 30-day mortality in a large series of
patients with sepsis.
Methods: We performed an observational, prospective, multicenter study in six Spanish Intensive Care Units. Serum levels of
MDA were measured in a total of 228 patients (145 survivors and 83 non-survivors) with severe sepsis and 100 healthy
controls.
Results: Serum levels of MDA were higher in severe septic patients than in healthy controls. Non-surviving septic patients
had higher MDA values than survivors. MDA serum levels were associated with severity markers (lactic acid, SOFA, APACHE-
II) and coagulation indices. Regression analysis showed that MDA serum levels were associated with 30-day survival (Hazard
ratio = 1.05; 95% confidence interval = 1.009–1.091; p = 0.016). Receiver operating characteristic analysis showed that the
area under curve of MDA serum levels to predict 30-day survival was 0.62 (95% CI = 0.56–0.69; P = 0.002). The risk of death in
septic patients with MDA serum levels above 4.11 nmol/mL was higher than in patients with lower values (Hazard
Ratio = 2.43; 95% CI = 1.49–3.94; p,0.001).
Conclusions: The novel findings of our study on severe septic patients, to our knowledge the largest series providing data
on the oxidative state, are that elevated MDA serum levels probably represent an unbalanced oxidant state and are related
with poor prognosis in patients with severe sepsis.
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Introduction
Severe sepsis is a common, resource-consuming and frequently
fatal condition, associated with as many deaths annually as acute
myocardial infarction [1,2].
The oxidant and antioxidant state in septic patients has been
scarcely assessed and then only in small series [3–6]. A higher
antioxidant state, determined by different compounds, has been
found in non-surviving than in surviving septic patients [4–6]. In
addition, a study of 12 patients by Ogilvie et al found higher
malondialdehyde (MDA) serum levels in non-surviving than in
surviving critically ill septic patients [3]; however, the sample size
was too small to demonstrate that MDA serum levels could be
used as a biomarker to predict clinical outcome of septic patients.
Oxidative damage is a result of an imbalance between oxidants
and antioxidants and includes oxidative modification of cellular
macromolecules, induction of cell death by apoptosis or necrosis,
as well as structural tissue damage. MDA is a low molecular weight
aldehyde that results from free radical attacks on polyunsaturated
fatty acids. MDA measurement can be considered a valuable
screening tool as a biomarker of oxidative damage [7].
Thus, the objective of this study was to determine whether
MDA serum levels are associated with severity and early mortality
in septic patients and whether these serum levels could be used as
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biomarkers to predict the clinical outcome of septic patients in a
large series of patients.
Methods
Design and Subjects
A multicenter, observational, prospective study was carried out
in six Spanish Intensive Care Units. The study was approved by
the Institutional Review Boards of the six hospitals recruiting
patients. All patients provided written informed consent to
participate in the study.
Inclusion criteria were the diagnosis of severe sepsis according
to the International Sepsis Definitions Conference criteria [8].
Exclusion criteria were: age ,18 years, pregnancy, lactation,
human immunodeficiency virus (HIV), white blood cell count
,1,000/ml, solid or hematological tumor, or immunosuppressive,
steroid or radiation therapy. A total of 228 patients with severe
sepsis and 100 healthy controls were included.
Variables Recorded
The following variables were recorded for each patient: sex, age,
diabetes mellitus, chronic renal failure (defined as glomerular
filtration rate (GFR) ,60 ml/mn per 1.73 m2), chronic obstructive
pulmonary disease (COPD), site of infection, creatinine, leuko-
cytes, lactic acid, platelets, international normalized ratio (INR),
activated partial thromboplastin time (aPTT), Acute Physiology
and Chronic Health Evaluation II (APACHE II) score [9], Sepsis-
related Organ Failure Assessment [SOFA] score [10], tumor
necrosis factor (TNF)-alpha, interleukin (IL)-10 and 30-day
mortality.
Blood samples were collected from 228 patients with severe
sepsis at the time of the diagnosis and from 100 healthy controls.
MDA Serum Level Analysis
Serum MDA levels were measured using thiobarbituric acid-
reactive substance (TBARS) method as described by Kikugawa
et al [11]. The pink complex of samples was extracted in n-
butanol. Each sample was placed in a 96-well plate and read at
535 nm in a microplate spectrophotometer reader (Benchmark
Plus, Bio-Rad, Hercules, CA, USA). The detection limit of this
assay was 0.079 nmol/ml; the intra- and inter-assay CV were
1.82% and 4.01%, respectively. The serum concentration of MDA
was expressed in nmol/ml. To avoid the possible dispersion of
MDA serum level results, all the samples were processed at the
same time, at the end of the recruitment process.
Statistical Methods
In a pilot study with 30 patients with severe sepsis, we found
that surviving patients showed lower circulating levels of MDA
(3.1461.22 nmol/mL) than non-survivors (3.6561.82 nmol/mL).
We calculated that 228 patients in a cohort study were needed in
order to demonstrate significant differences in the circulating levels
of MDA between groups, for a power of 80% and a type I error
rate of 5%.
Continuous variables are reported as medians and interquartile
ranges. Categorical variables are reported as frequencies and
percentages. Comparisons of continuous variables between groups
were carried out using Wilcoxon-Mann-Whitney test. Compari-
sons between groups for categorical variables were carried out
with chi-square test. The association between continuous variables
was carried out using Spearmans rank correlation coefficient or
Spearman’s rho coefficient. We plotted a receiver operating
characteristic (ROC) curve using survival at 30 days as classifica-
tion variable and MDA level as prognostic variable. The cut-off
prognostic value of the serum levels of MDA was selected with the
likelihood ratio between sensitivity and 1-specificity (likelihood
ratio = 2.0). Analysis of survival at 30 days with Kaplan-Meier
method curve and comparisons by log-rank test were carried out
using MDA serum levels lower/higher than 4.11 nmol/mL as the
independent variable and survival at 30 days as the dependent
variable. Cox regression analysis was applied to determine the
independent contribution of MDA serum levels on the prediction
of 30-day mortality. To avoid collinearity effect [12], we only
included age, lactic acid, APACHE-II and aPTT as co-predictors.
Hazard ratio and 95% confidence intervals were calculated as
measures of the clinical impact of the predictor variables. A P
value of less than 0.05 was considered statistically significant.
Statistical analyses were performed with SPSS 17.0 (SPSS Inc.,
Chicago, IL, USA) and NCSS 2000 (Kaysville, Utah).
Results
We found lower MDA serum levels in septic patients than in
healthy controls; however, there were no significant differences
between both groups in terms of age and sex (Table 1).
Comparison of demographic and clinical parameters between
non-surviving (n = 83) and surviving septic patients (n = 145) are
shown in Table 2. No differences were observed regarding sex,
chronic renal failure, COPD, diabetes mellitus, ischemic heart
disease, site of infection, microorganism responsible, bloodstream
infection, antimicrobial treatment and TNF-alpha; however, the
non-surviving septic patients showed higher age, higher levels of
lactic acid and IL-10 and creatinine, increased SOFA and
APACHE-II scores, prolonged aPTT, and reduced platelet count.
Moreover, non-surviving patients had higher serum levels of MDA
(p = 0.002) than survivors.
Correlations of MDA serum levels with lactic levels, age,
APACHE-II, SOFA, platelets, INR, aPTT, TNF-alpha and IL-10
are shown in Table 3. MDA serum levels positively correlated with
lactic acid, SOFA, APACHE-II, INR, aPTT, TNF-alpha and IL-
10, and negatively with platelet count.
Cox regression analysis showed that MDA serum levels were
associated with survival at 30 days (Hazard ratio = 1.05; 95%
confidence interval = 1.009–1.091; p = 0.016) after controlling for
age, lactic acid levels, APACHE-II and aPTT (Table 4).
Table 1. Demographic’ characteristics of healthy controls and septic patients.
Healthy controls (n = 100) Septic patients (n = 228) p-value
Gender male – n (%) 62 (62.0) 150 (65.8) 0.53
Age - median years (p 25–75) 59 (47–70) 60 (48–71) 0.74
MDA - median nmol/mL(p 25–75) 1.11 (0.78–1.51) 3.20 (2.06–4.86) ,0.001
doi:10.1371/journal.pone.0053741.t001
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Kaplan-Meier survival analysis showed that patients with MDA
serum levels higher than 4.11 nmol/mL had a lower probability of
survival at 30 days (log-rank = 18.1; Hazard Ratio = 2.4 (95%
CI = 1.49–3.94); P,0.001) than patients with lower levels
(Figure 1).
We performed a ROC analysis to determine whether MDA
serum levels could be used to predict outcomes in septic patients,
and found that the area under curve of the MDA serum levels to
predict 30-days survival was 0.62 (95% CI = 0.56–0.69; P = 0.002)
(Figure 2).
Table 2. Patients’demographic and clinical characteristics of septic patients.
Survival (n = 145) Non-survival (n = 83) p-value
Gender male – n (%) 94 (64.8) 56 (67.5) 0.77
Age - median years (p 25–75) 55 (44–66) 64 (55–74) 0.001
Diabetes mellitus – n (%) 41 (28.3) 31 (37.3) 0.18
Chronic renal failure – n (%) 8 (5.5) 8 (9.6) 0.28
COPD – n (%) 16 (11.0) 13 (15.7) 0.31
Ischemic heart disease - n (%) 13 (9.0) 6 (7.2) 0.80
Site of infection 0.68
? Respiratory - n (%) 81 (55.9) 48 (57.8)
? Abdominal - n (%) 39 (26.9) 22 (26.5)
? Neurological 3 (2.1) 0
? Urinary - n (%) 8 (5.5) 5 (6.0)
? Skin - n (%) 8 (5.5) 3 (3.6)
? Endocarditis - n (%) 6 (4.1) 4 (4.8)
? Osteomyelitis - n (%) 0 1 (1.2)
Microorganism responsibles
? Unkwon - n (%) 77 (53.1) 47 (56.6) 0.68
? Gram-positive- n (%) 32 (22.1) 19 (22.9) 0.87
? Gram-negative- n (%) 35 (24.1) 17 (20.5) 0.62
? Fungii- n (%) 4 (2.8) 4 (4.8) 0.47
? Anaerobe- n (%) 1(0.7) 1 (1.2) 0.99
Bloodstream infection 22 (15.2) 11(13.3) 0.84
Empiric antimicrobial treatment adequate 0.85
? Unkown due to negative cultures- n (%) 77 (53.1) 47 (56.6)
? Adequate - n (%) 58 (40.0) 31 (37.3)
? Unkown due to antigenuria diagnosis-n(%) 4 (2.8) 3 (3.6)
? Inadequate- n (%) 6 (4.1) 2 (2.4)
Betalactamic more aminoglycoside - n (%) (%)aminoglycoside- n (%) 28 (19.6) 20 (24.1) 0.50
Betalactamic more quinolone - n (%) 79 (55.2) 44 (53.0) 0.78
Pa02/FI02 ratio - median (p 25–75) 177 (118–261) 180 (104–247) 0.41
Creatinine (mg/dl) - median (p 25–75) 1.20 (0.80–1.90) 1.50 (0.90–2.80) 0.03
Bilirubin (mg/dl) - median (p 25–75) 0.90 (0.46–1.55) 1.10 (0.50–2.50) 0.49
Leukocytes -median*103/mm3 (p 25–75) 14.9 (10.0–20.4) 15.1 (8.7–20.4) 0.83
Lactic acid - median mmol/L (p 25–75) 2.00 (1.10–3.60) 3.50 (1.40–6.00) ,0.001
Platelets - median*103/mm3 (p 25–75) 192 (131–273) 129 (77–219) ,0.001
INR - median (p 25–75) 1.27 (1.10–1.54) 1.41 (1.14–1.88) 0.01
aPTT - median seconds (p 25–75) 32 (28–41) 36 (29–46) 0.006
SOFA score - median (p 25–75) 9 (7–11) 11 (9–15) ,0.001
APACHE-II score - median (p 25–75) 19 (14–22) 23 (18–28) ,0.001
MDA - median nmol/mL(p 25–75) 2.89 (2.04–4.05) 3.93 (2.45–7.37) 0.002
TNF-alpha median pg/ml (percentile 25–75) 30 (20–50) 39 (18–75) 0.41
IL-10 - median pg/ml (percentile 25–75) 11 (5–37) 40 (8–138) 0.004
COPD = chronic obstructive pulmonary disease; PaO2/FIO2 = pressure of arterial oxygen/fraction inspired oxygen; aPTT = Activated partial thromboplastin time;
INR = International normalized ratio; APACHE-II = Acute Physiology and Chronic Health Evaluation-II; SOFA = Sepsis-related Organ Failure Assessment; TNF = Tumor
necrosis factor; IL = Interleukin; data are presented as number (percentage) or median (interquartile range).
doi:10.1371/journal.pone.0053741.t002
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Discussion
To our knowledge, this study includes the largest series
providing data on the oxidative state in patients with severe
sepsis. The most relevant findings were: a) higher serum levels of
MDA in survivin and non-surviving severe septic patients than in
healthy controls, b) there was a correlation between MDA serum
levels and several indicators of severity in sepsis, c) the non-
surviving septic patients had higher MDA serum levels than the
survivors, and d) MDA serum levels could be used to predict
outcomes in septic patients. Taken together, these results indicate
that alteration of the oxidative state may be of great pathophys-
iological significance in septic patients.
We found that severe septic patients had higher serum levels of
MDA than controls. These findings are consistent with the results
of other small series with only 12 patients [3].
In our study, non-surviving septic patients had significantly
higher MDA serum levels than survivors. These findings are
consistent with the results of small series. Higher MDA serum
levels have been reported in non-surviving than in surviving
patients between 60 critically ill patients [13] and also specifically
between 12 septic patients [3]; however, the sample size was too
small to demonstrate that MDA serum levels are independently
associated with survival in these series. The present study is the
first to report that MDA serum levels could be used as a biomarker
to predict the clinical outcome of septic patients. The large sample
Table 3. Correlation of MDA serum levels with lactic acid,
SOFA, APACHE-II, age, coagulation markers and interleukins in
severe septic patients.
MDA serum levels
Lactatemia (mmol/L) rho = 0.26; P,0.001
SOFA score (punctuation) rho = 0.40; P,0.001
APACHE-II score (punctuation) rho = 0.24; P,0.001
Age rho = 0.10; P = 0.06
Platelets rho = -0.33; P,0.001
INR rho = 0.35; P,0.001
aPTT rho = 0.21; P = 0.001
TNF-alpha rho = 0.36; P,0.001
IL-10 rho = 0.34; P,0.001
SOFA = Sepsis-related Organ Failure Assessment score; APACHE-II = Acute
Physiology and Chronic Health Evaluation-II; INR = International normalized
ratio; aPTT = Activated partial thromboplastin time; TNF = Tumor necrosis factor;
IL = Interleukin; rho = Spearmans rank correlation coefficient.
doi:10.1371/journal.pone.0053741.t003




MDA serum levels 1.05 1.009–1.091 0.016
Age 1.02 1.000–1.035 0.055
Lactic acid 1.08 1.003–1.167 0.041
APACHE-II 1.04 1.007–1.076 0.018
aPTT 1.01 1.003–1.022 0.012
APACHE-II = Acute Physiology and Chronic Health Evaluation-II;
aPTT = Activated partial thromboplastin time.
doi:10.1371/journal.pone.0053741.t004
Figure 1. Survival curves at 30 days using MDA serum levels higher or lower than 4.11 nmol/mL.
doi:10.1371/journal.pone.0053741.g001
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size, compared to previous studies, allowed us carried out a
regression analysis to determine the independent contribution of
MDA on the prediction of 30-day mortality. The imbalance
favouring the oxidant state in non-surviving patients could lead to
an increase of free radicals and these may contribute to cellular
dysfunction, organ failure and finally death [14,15].
Interestingly, we observed a significant correlation between
MDA serum levels and several indicators of severity in sepsis,
including lactic acid, APACHE-II and SOFA scores, and
biomarkers of coagulation. Previous studies have reported a
positive correlation between MDA and severity in critically
patients [13] and in diabetic patients [16].
The strengths of our study are that it was a multicenter study
(which increases the external applicability of results to other
similar units) and the large sample size (that allowed us to increase
the accuracy of the parameters analysed with respect to previous
studies). Certain limitations should be recognized, such as the fact
that no analysis of MDA serum levels during follow-up was
performed. Measuring other compounds of oxidant and antiox-
idant states would be desirable in order to better evaluate this
balance.
From a therapeutic perspective, the development of modulators
of antioxidant/oxidant state could be used as a new class of drugs
for the treatment of severe sepsis. In rats the administration of
melatonin has been shown to reduce MDA levels and increase the
levels of other antioxidant compounds such as glutathione
reductase (GSH) and superoxide dismutase (SOD) [17–19]. In
patients, the use of melatonin has reduced MDA serum levels in
asphyxiated newborns [20] and septic newborns [21], and in adult
burn patients it has reduced MDA serum levels and mortality [22].
Conclusion
The novel findings of our study on severe septic patients, to our
knowledge the largest series providing data on the oxidative state,
are that elevated MDA serum levels probably represent an
unbalanced oxidant state and are related with poor prognosis in
patients with severe sepsis.
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